Benitec Biopharma Inc.

NasdaqCM:BNTC Stock Report

Market Cap: US$216.4m

Benitec Biopharma Past Earnings Performance

Past criteria checks 0/6

Benitec Biopharma's earnings have been declining at an average annual rate of -29.5%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 98.2% per year.

Key information

-29.5%

Earnings growth rate

30.2%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-98.2%
Return on equity-46.0%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Oct 02
Companies Like Benitec Biopharma (NASDAQ:BNTC) Are In A Position To Invest In Growth

Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Nov 30
Most Shareholders Will Probably Find That The Compensation For Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Is Reasonable

Benitec Biopharma prices of $18M securities offering

Sep 13

Benitec GAAP EPS of -$2.23, revenue of $0.07M

Sep 02

We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

Jan 13
We're A Little Worried About Benitec Biopharma's (NASDAQ:BNTC) Cash Burn Rate

We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Sep 30
We Think Benitec Biopharma (NASDAQ:BNTC) Needs To Drive Business Growth Carefully

Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

May 12
Will Benitec Biopharma (NASDAQ:BNTC) Spend Its Cash Wisely?

Benitec Bio secures $13M capital via equity offering

Apr 28

Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

Jan 27
Can Benitec Biopharma (NASDAQ:BNTC) Afford To Invest In Growth?

How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Dec 02
How Does Benitec Biopharma's (NASDAQ:BNTC) CEO Salary Compare to Peers?

Revenue & Expenses Breakdown

How Benitec Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:BNTC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-22716
31 Mar 240-22615
31 Dec 230-22616
30 Sep 230-20615
30 Jun 230-20613
31 Mar 230-20713
31 Dec 220-19712
30 Sep 220-18711
30 Jun 220-18711
31 Mar 220-17710
31 Dec 210-18611
30 Sep 210-1679
30 Jun 210-1477
31 Mar 210-1376
31 Dec 200-1174
30 Sep 200-1073
30 Jun 200-863
31 Mar 201-753
31 Dec 191-653
30 Sep 197-244
30 Jun 1912355
31 Mar 1912255
31 Dec 1812265
30 Sep 188-365
30 Jun 183-965
31 Mar 184-975
31 Dec 176-775
30 Sep 175-775
30 Jun 179-475
31 Mar 177-776
31 Dec 167-877
30 Sep 167-1297
30 Jun 163-18910
31 Mar 163-18910
31 Dec 152-1689
30 Sep 152-1268
30 Jun 153-965
31 Mar 153-654
31 Dec 141-753
30 Sep 141-753
30 Jun 141-754
31 Mar 141-543
31 Dec 131-342

Quality Earnings: BNTC is currently unprofitable.

Growing Profit Margin: BNTC is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: BNTC is unprofitable, and losses have increased over the past 5 years at a rate of 29.5% per year.

Accelerating Growth: Unable to compare BNTC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BNTC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: BNTC has a negative Return on Equity (-46.04%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies